François Trottein Selected Research

Galactosylceramides (Galactocerebrosides)

1/2020	Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice.
11/2019	Bacterial immunogenic α-galactosylceramide identified in the murine large intestine: dependency on diet and inflammation.
1/2017	Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses.
11/2016	Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza.
10/2016	Mechanisms of Invariant NKT Cell Activity in Restraining Bacillus anthracis Systemic Dissemination.
7/2014	Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
9/2012	Key role for respiratory CD103(+) dendritic cells, IFN-γ, and IL-17 in protection against Streptococcus pneumoniae infection in response to α-galactosylceramide.
2/2012	Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
10/2011	A detrimental role for invariant natural killer T cells in the pathogenesis of experimental dengue virus infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

François Trottein Research Topics

Disease

30	Infections 01/2022 - 05/2003
11	Inflammation (Inflammations) 01/2021 - 04/2003
10	Neoplasms (Cancer) 05/2022 - 05/2007
8	Human Influenza (Influenza) 01/2022 - 06/2013
7	Pneumonia (Pneumonitis) 11/2018 - 07/2010
6	Bacterial Infections (Bacterial Infection) 01/2021 - 09/2012
6	Pneumococcal Infections 01/2020 - 09/2012
5	Superinfection 01/2022 - 06/2013
5	Schistosomiasis (Bilharziasis) 05/2014 - 07/2002
4	COVID-19 01/2022 - 01/2022
4	Asthma (Bronchial Asthma) 10/2010 - 01/2004
3	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022 - 10/2015
3	Neoplasm Metastasis (Metastasis) 01/2018 - 01/2008
3	Melanoma (Melanoma, Malignant) 01/2017 - 01/2008
3	Virus Diseases (Viral Diseases) 01/2017 - 02/2006
2	Breast Neoplasms (Breast Cancer) 01/2018 - 12/2011
2	Autoimmune Diseases (Autoimmune Disease) 10/2016 - 05/2007
2	Reinfection 05/2014 - 01/2012
2	Hypersensitivity (Allergy) 10/2010 - 07/2010
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021
1	Dysbiosis 01/2020
1	Whooping Cough (Pertussis) 11/2018
1	Carcinoma (Carcinomatosis) 09/2017
1	Bacterial Pneumonia 11/2016
1	Pneumococcal Pneumonia 11/2016
1	Atrophy 01/2014
1	Communicable Diseases (Infectious Diseases) 06/2013
1	Ulcerative Colitis 01/2013
1	Colitis 01/2013

Drug/Important Bio-Agent (IBA)

9	Galactosylceramides (Galactocerebrosides)IBA 01/2020 - 10/2011
9	CytokinesIBA 11/2018 - 07/2002
5	VaccinesIBA 01/2020 - 09/2003
5	LipidsIBA 09/2012 - 01/2004
4	Antiviral Agents (Antivirals)IBA 01/2022 - 11/2016
4	Volatile Fatty AcidsIBA 01/2022 - 01/2020
4	LigandsIBA 01/2021 - 02/2007
4	Interleukin-17 (Interleukin 17)IBA 01/2021 - 09/2012
4	Interleukin-22 (IL-22)IBA 01/2018 - 03/2012
3	InterleukinsIBA 01/2022 - 02/2007
3	AntigensIBA 05/2014 - 02/2007
3	Immunoglobulin G (IgG)IBA 01/2012 - 05/2003
3	ProstaglandinsIBA 02/2007 - 04/2003
2	Acetates (Acetic Acid Esters)FDA Link 01/2022 - 01/2020
2	16S Ribosomal RNAIBA 01/2022 - 01/2021
2	Pharmaceutical PreparationsIBA 01/2022 - 05/2014
2	Toll-Like Receptor 5IBA 01/2021 - 10/2015
2	FlagellinIBA 01/2021 - 10/2015
2	SmokeIBA 01/2021 - 01/2013
2	MART-1 AntigenIBA 01/2020 - 01/2017
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2020 - 01/2017
2	Interleukin-7 (Interleukin 7)IBA 01/2020 - 01/2018
2	Messenger RNA (mRNA)IBA 11/2018 - 06/2007
2	Proteins (Proteins, Gene)FDA Link 11/2018 - 12/2011
2	Dexamethasone (Maxidex)FDA LinkGeneric 11/2016 - 01/2014
2	prostaglandin D2 receptorIBA 01/2014 - 03/2005
2	Immunoglobulin E (IgE)IBA 01/2012 - 03/2005
2	EicosanoidsIBA 01/2008 - 01/2004
2	Prostaglandin D2IBA 01/2008 - 01/2004
2	PPAR gammaIBA 01/2004 - 05/2003
2	GlycoconjugatesIBA 05/2003 - 07/2002
1	clofoctolIBA 01/2022
1	PropionatesIBA 01/2021
1	Nonesterified Fatty Acids (NEFA)IBA 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 01/2020
1	GangliosidesIBA 01/2019
1	Secretory Immunoglobulin A (SIgA)IBA 11/2018
1	interleukin 20 (IL-20)IBA 11/2018
1	Interferon Type IIBA 10/2018
1	chenodeoxycholate sulfate conjugate (CDCS)IBA 10/2018
1	Interleukin-6 (Interleukin 6)IBA 10/2018
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 05/2017
1	Immunologic Factors (Immunomodulators)IBA 05/2017
1	AutoantigensIBA 01/2017
1	4-(2-amino-1-methyl-2-oxoethyl)phenyl trifluoromethanesulfonateIBA 01/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2016
1	Interferon-gamma (Interferon, gamma)IBA 11/2016
1	Anti-Bacterial Agents (Antibiotics)IBA 10/2015
1	Praziquantel (Biltricide)FDA Link 05/2014
1	Bleomycin (Blenoxane)FDA LinkGeneric 01/2014
1	ChemokinesIBA 01/2014
1	OsteopontinIBA 01/2014
1	Leukemia Inhibitory FactorIBA 01/2014
1	GlucocorticoidsIBA 01/2014
1	Dextrans (Dextran)FDA Link 01/2013
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2013
1	CD1d AntigensIBA 02/2012
1	KRN 7000 (KRN7000)IBA 02/2012
1	HLA-DR Antigens (HLA-DR)IBA 01/2012
1	OvalbuminIBA 01/2012
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 12/2011
1	Interleukin-12 (IL 12)IBA 12/2011
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2011
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 12/2011
1	Cell Adhesion MoleculesIBA 12/2011
1	InterferonsIBA 10/2010
1	Pattern Recognition ReceptorsIBA 10/2010

Therapy/Procedure

5	Therapeutics 01/2022 - 07/2014
3	Immunotherapy 05/2022 - 07/2014
2	Intranasal Administration 11/2018 - 07/2010